NCT05651178View on ClinicalTrials.gov

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 12, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

August 31, 2025

Conditions
Central Nervous System Lymphoma
Interventions
DRUG

Human CD19-CD22 Targeted T Cells Injection

Autologous genetically modified anti-CD19/CD22 CAR transduced T cells

Trial Locations (1)

330006

RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

Sponsors
All Listed Sponsors
collaborator

Second Affiliated Hospital of Nanchang University

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY